Truist Financial Forecasts Strong Price Appreciation for Inspire Medical Systems (NYSE:INSP) Stock

Inspire Medical Systems (NYSE:INSP) had its price objective hoisted by research analysts at Truist Financial from $50.00 to $54.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Truist Financial’s price target suggests a potential upside of 4.14% from the stock’s previous close.

INSP has been the topic of several other research reports. Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Robert W. Baird lowered their price objective on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating for the company in a research note on Tuesday, May 5th. Oppenheimer reissued a “market perform” rating on shares of Inspire Medical Systems in a research report on Monday, June 15th. Summit Redstone set a $39.00 target price on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Finally, Mizuho lowered their price target on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Inspire Medical Systems has an average rating of “Hold” and a consensus price target of $81.26.

Inspire Medical Systems Trading Up 2.7%

Shares of NYSE INSP traded up $1.35 during trading hours on Thursday, reaching $51.85. The stock had a trading volume of 212,214 shares, compared to its average volume of 1,192,090. Inspire Medical Systems has a 52-week low of $38.91 and a 52-week high of $147.03. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of 11.55, a P/E/G ratio of 4.98 and a beta of 0.71. The business’s fifty day moving average price is $44.11 and its two-hundred day moving average price is $59.17.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The business had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. During the same period in the previous year, the company posted $0.10 EPS. Inspire Medical Systems’s revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Equities research analysts anticipate that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.

Institutional Trading of Inspire Medical Systems

Institutional investors have recently made changes to their positions in the business. Rheos Capital Works Inc. grew its stake in Inspire Medical Systems by 124.0% during the 4th quarter. Rheos Capital Works Inc. now owns 117,400 shares of the company’s stock valued at $10,828,000 after purchasing an additional 65,000 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Inspire Medical Systems by 395.9% during the fourth quarter. SG Americas Securities LLC now owns 38,449 shares of the company’s stock worth $3,546,000 after purchasing an additional 30,695 shares during the period. Banque Pictet & Cie SA lifted its holdings in shares of Inspire Medical Systems by 797.5% during the fourth quarter. Banque Pictet & Cie SA now owns 24,474 shares of the company’s stock worth $2,257,000 after purchasing an additional 21,747 shares during the period. Aberdeen Group plc boosted its position in Inspire Medical Systems by 16.3% in the fourth quarter. Aberdeen Group plc now owns 460,901 shares of the company’s stock valued at $42,509,000 after buying an additional 64,561 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in Inspire Medical Systems in the fourth quarter valued at approximately $24,441,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.